|
Characteristics
|
Samples
|
|
Cases/Controls
|
226/200
|
|
Age at diagnosis, mean ± SD (years)
|
41 ± 11
|
|
Range (years)
|
27 – 67
|
|
Menopausal Status
|
No. (%)
|
|
Premenopausal
|
162(71.68)
|
|
Postmenopausal
|
63(27.87)
|
|
Missing
|
1(0.44)
|
|
Estrogen receptor
| |
|
Positive
|
130 (57.52)
|
|
Negative
|
78(34.51)
|
|
Missing
|
18 (7.96)
|
|
Progesterone receptor
| |
|
Positive
|
136 (59.29)
|
|
Negative
|
72(31.85)
|
|
Missing
|
18 (7.96)
|
|
Estrogen/Progesterone receptor
| |
|
ER+/PR+
|
111 (49.11)
|
|
ER+/PR−
|
25 (11.06)
|
|
ER−/PR+
|
19 (8.40)
|
|
ER−/PR−
|
53 (23.45)
|
|
Tumor size
| |
|
<2 cm
|
30 (13.27)
|
|
>2 cm
|
105 (46.46)
|
|
>5 cm
|
41(18.14)
|
|
Tumor of any size with extension
|
37 (16.37)
|
|
Histological grade
| |
|
1
|
8 (3.53)
|
|
2
|
141 (62.38)
|
|
3
|
59 (26.10)
|
|
Lymph node status
| |
|
Negative
|
86(38.55)
|
|
Positive
|
132 (58.40)
|
|
Distant metastases
| |
|
Negative
|
170(75.22)
|
|
Positive
|
38 (16.81)
|
- ER estrogen receptors, PR progesterone receptors
